Tocilizumab (Acterma) is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients. Explore the live graph.
Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More
Patients with COVID-19 often also face cardiovascular challenges and associated comorbidities. Understanding how repositioned drugs to treat COVID-19 may impact the cardiovascular health of patients is important.Live Graph Detail: Targets of the drugs are included (e.g. RNA dependent RNA polymerase, target of remdesivir, IL-7, target of IL-6 inhibitors). Explore the live graph.
There is growing amount of evidence to suggest the use of pharmaceuticals that target the Renin-Angiotensin System (e.g. angiotensin 1-7, ARBs and ACE inhibitors) may be beneficial in the treatment of COVID-19. This graph shows the interconnections among these classes of drugs, and SARS-CoV-2 via key genes implicated in this pathway. mediated. Explore the live … Read More
Azithromycin is being tested in COVID-19 patients. Although it is a potent antibiotic, in the COVID-19 setting, it likely acts as an anti-inflammatory agent. Its exact MoA in the disease, however, remains to be elucidated. Explore the live graph.